Trial Profile
BRE 17107: A Phase Ib/II Trial of Atezolizumab (an Anti-PD-L1 Monoclonal Antibody) With Cobimetinib (a MEK1/2 Inhibitor) or Idasanutlin (an MDM2 Antagonist) in Metastatic ER+ Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Cobimetinib (Primary) ; Idasanutlin (Primary)
- Indications Advanced breast cancer; Carcinoma
- Focus Adverse reactions; Therapeutic Use
- 10 Aug 2021 Status changed from active, no longer recruiting to discontinued.
- 01 Dec 2019 Status changed from recruiting to active, no longer recruiting.
- 27 Jun 2019 Planned number of patients changed from 92 to 80.